AzTrials
AzTrials

Phantom LimbPhase 3CAPDAFNCT00427947

Leg Amputation and Continuous Sciatic Nerve Block

A Phase 3 study of Phantom Limb and Leg Amputation, run by University Hospital, Bordeaux at 1 site in France.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

Analgesia following leg amputation is based on morphine administration. For elderly patients of ASA physical status 2 or 3, morphine sparing is possible when perinervous block techniques are used. Phantom limb pain complicates leg amputation in 50 to 80% of cases. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Phantom Limb, Leg Amputation
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
6 participants
Where
1 siteFrance
Study dates
Dec 2006to Dec 2009
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients scheduled for leg amputation following arteritis
  • ASA score: 2-3
  • Informed consent obtained from the patient

Who cannot join

  • Patients involved in another clinical trial
  • Post-infection OR post traumatic leg amputation
  • Blood coagulation disorders
  • Local anesthetic, morphine, or paracetamol allergy
  • Local inflammatory signs
  • Pregnant or breastfeeding women
  • Patients with protective supervision

Trial locations and contacts

1 site in 1 country.

France1 site
  • Département d'anesthésie réanimation I, Hopital Pellegrin, CHU de Bordeaux

    Bordeaux, 33076

Other trials in France

About this study

Official title: Continuous Popliteal Sciatic Nerve Block Interest in Postoperative Pain Management for Patients With Leg Amputation

Analgesia following leg amputation is based on morphine administration. For elderly patients of ASA physical status 2 or 3, morphine sparing is possible when perinervous block techniques are used. Phantom limb pain complicates leg amputation in 50 to 80% of cases. Prevention of these pains has been studied in various clinical trials but the interest of perinervous block technique remains to be evaluated.

The purpose of the study is to evaluate the benefit of perioperative locoregional analgesia by ropivacaine via a popliteal sciatic catheter on intravenous morphine consumption during the 72 first postoperative hours following leg (below knee) amputation The study will be randomized, double blinded, controlled clinical trial and 84 patients undergoing leg amputation (below knee) will be included Patients will be divided into 2 groups: one group of patients who will benefit perioperative locoregional analgesia by ropivacaine via a popliteal sciatic catheter and morphine for analgesia and the other one who will benefit placebo through the catheter and morphine.

The investigators will evaluate the efficacy of the continuous popliteal sciatic nerve block in postoperative analgesia after leg amputation and prove the efficacy of a perioperative analgesia by continuous popliteal sciatic nerve block to prevent phantom limb pain after leg amputation in patients of ASA physical status 2 or 3.

Read the detailed description

Introduction:

Analgesia following leg amputation is based on morphine administration. For elderly patients of ASA physical status 2 or 3, morphine sparing is possible when perinervous block techniques are used. Indeed, per operative placement of a perinervous catheter by the surgeon allows a morphine consumption decrease of about 30%. Nevertheless, the interest of a sciatic block providing analgesia in the tibial and fibular territories has still to be assessed in this indication.

Phantom limb pain complicates leg amputation in 50 to 80% of cases. Risk factors of this complication are numerous, from central or peripheral origin. Phantom limb pain postpones patients' social and professional rehabilitation, and results in an increased medical consumption. Prevention of these pains has been studied in various clinical trials, and results need confirmation. Thus, epidural analgesia alone does not decrease the long term incidence of phantom limb pain.

Objectives:

Primary : To compare intravenous morphine consumption during the 72 first postoperative hours following leg (below knee) amputation of patients randomly assigned in two groups. One group benefit from perioperative locoregional analgesia by ropivacaine via a popliteal sciatic catheter, the other group is given placebo through the catheter.

Secondary :

  • To assess tolerance and adverse effects (myalgia, infection, adverse effects of local anaesthetics) of the popliteal sciatic catheter during the 72 first postoperative hours and on the 7th postoperative day, in patients with ASA physical status 2 or 3
  • To compare tolerance and adverse effects of morphine during the protocol in the 2 groups of patients
  • To assess the long term effects of the preoperative continuous popliteal sciatic nerve block: incidence of stump pain and phantom limb pain, time of outbreak, intensity (VAS), characteristics (French version of the McGill Pain Questionnaire and DN4 questionnaire), and the analgesic consumption over a year.
  • To assess the possibility for the patients to use a prosthesis

Population:

Eighty four patients scheduled for leg amputation (below knee), randomly allocated in 2 groups of forty patients, according to the type of analgesia. Patients were enrolled in the general and vascular surgery unit, CHU (University Hospital) Pellegrin Bordeaux.

Methods:

Randomised clinical trial, with two parallel groups, with direct individual benefit, double-blinded, realised on a population of patients undergoing leg amputation, comparing different clinical parameters of postoperative pain evaluation, and outbreak of phantom limb pain according to the group of analgesia.

  • One group of patients with locoregional analgesia associated with morphine administration (assessed treatment)
  • One group of patients with morphine analgesia only (reference treatment). Patients will be followed for one year. This study will last 3 years in a general and vascular surgery unit, inclusion will be realised during 34 months by anaesthetists and surgeons, an extension of this study for one year will be done with the objective of a cohort follow-up.

Statistical analysis will be done with intention to treat.

Anticipated results:

To prove the efficacy of the continuous popliteal sciatic nerve block in postoperative analgesia after leg amputation.

To prove the efficacy of a perioperative analgesia by continuous popliteal sciatic nerve block to prevent phantom limb pain after leg amputation in patients of ASA physical status 2 or 3.

Being tested
ropivacaine/placebo
Keywords
phantom limb pain, amputation, anesthetics, local, postoperative analgesia, ropivacaine, analgesia
Medical subject headings
Phantom Limb, Agnosia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ropivacaine/placeboDrug

    Continuous sciatic nerve bloc

Study groups in NCT00427947
Study groupRoleWhat they receive
1ExperimentalContinuous sciatic nerve bloc : ropivacaine infusion
Receives: Drug: ropivacaine/placebo
2Placebo comparatorContinuous sciatic nerve bloc : NaCl Infusion
Receives: Drug: ropivacaine/placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total intravenous morphine consumption

    Measured: during the first 72 postoperative hours following leg (below knee) amputation

Secondary outcomes (4)
  1. tolerance and adverse effects (myalgia, infection, adverse effects of local anaesthetics) of the popliteal sciatic catheter, in patients with ASA physical status 2 or 3

    Measured: during the 72 first postoperative hours and on the 7th postoperative day

  2. tolerance and adverse effects of morphine during the protocol in the 2 groups of patients

    Measured: during the first 72 postoperative hours

  3. incidence of stump pain and phantom limb pain, time of outbreak, intensity (VAS), characteristics (French version of the McGill Pain Questionnaire and DN4 qu

    Measured: 1, 3, 6 and 12 months postoperative

  4. use of prosthesis

    Measured: 1, 3, 6 and 12 months postoperative

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jan 2007 (estimated)
  2. Study startDec 2006
  3. Primary completionApr 2009
  4. Study completionDec 2009

Why it stopped: lack of patients

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
6 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00427947
Sponsor's protocol ID
9440-05
Other IDs
2004-037
Acronym
CAPDAF
Status last verified
Dec 2009
First submitted
26 Jan 2007
Last updated
29 Dec 2009
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study of Phantom Limb and Leg Amputation, run by University Hospital, Bordeaux at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 29 Dec 2009. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was stopped early (reason given: lack of patients). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total intravenous morphine consumption (time frame: during the first 72 postoperative hours following leg (below knee) amputation). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Dec 2009.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in